Quick Answer
Cartesian Therapeutics, Inc. reported Total Revenue of $2.80 million for fiscal year 2025.
Cartesian Therapeutics, Inc. — Key Financials by Year
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|---|
| Total Revenue | $2.80M -92.8% |
$38.91M +49.6% |
$26.00M -76.5% |
$110.78M +30.2% |
$85.08M +412.6% |
$16.60M +148.6% |
| Revenue (ASC 606) | $400.0K -99.0% |
$38.27M +47.2% |
$26.00M -76.5% |
$110.78M +30.2% |
$85.08M +412.6% |
$16.60M +148.6% |
| Net Income | -$130.30M -68.3% |
-$77.42M +64.8% |
-$219.71M -721.0% |
$35.38M +237.7% |
-$25.69M +62.7% |
-$68.88M -24.4% |
| Diluted EPS | -$5.02 -11.8% |
-$4.49 +91.0% |
-$49.76 -49860.0% |
$0.10 +145.5% |
-$0.22 +67.6% |
-$0.68 +44.3% |
| Total Assets | $296.41M -31.9% |
$435.02M +42.6% |
$305.05M +83.9% |
$165.89M +3.8% |
$159.88M -3.4% |
$165.44M +66.2% |
| Cash and Equivalents | $125.14M -41.1% |
$212.61M +176.4% |
$76.91M -27.7% |
$106.44M -6.7% |
$114.06M -17.8% |
$138.69M +54.3% |
| Stockholders Equity | -$126.24M -1755.9% |
-$6.80M +98.5% |
-$440.18M -569.1% |
$93.83M +316.6% |
$22.52M +225.1% |
-$18.01M -314.4% |
| R&D Expense | $58.03M +28.7% |
$45.10M -36.7% |
$71.26M -1.5% |
$72.38M +5.3% |
$68.74M +26.1% |
$54.51M +27.5% |
| Operating Income | -$143.41M -226.7% |
-$43.90M +49.2% |
-$86.42M -694.4% |
$14.54M +416.2% |
-$4.60M +91.9% |
-$56.82M -8.3% |
| Shares Outstanding | 26.01M +0.9% |
25.77M +377.4% |
5.40M -96.5% |
153.04M +23.8% |
123.62M +14.4% |
108.07M +25.2% |
Most Recent Quarter
| Metric | Quarter Ending | Value | YoY | QoQ |
|---|---|---|---|---|
| Total Revenue | September 30, 2025 | $452.0K | +16.8% | +51.7% |
| Revenue (ASC 606) | September 30, 2025 | $0.00 | — | — |
| Net Income | September 30, 2025 | -$35.90M | -48.5% | -326.0% |
| Diluted EPS | September 30, 2025 | -$1.38 | -22.1% | -376.0% |
| Total Assets | September 30, 2025 | $372.68M | -18.2% | -4.2% |
| Cash and Equivalents | September 30, 2025 | $143.38M | -34.6% | -10.6% |
| Stockholders Equity | September 30, 2025 | -$35.84M | -4866.5% | -1318.4% |
| R&D Expense | September 30, 2025 | $13.80M | +21.1% | -7.2% |
| Operating Income | September 30, 2025 | -$21.07M | -19.9% | +3.4% |
| Shares Outstanding | September 30, 2025 | 26.00M | +8.8% | +0.0% |
- Cartesian Therapeutics, Inc. reported Total Revenue of $2.80 million for fiscal year 2025.
- Cartesian Therapeutics, Inc. showed a decrease of -92.8% in Total Revenue compared to the prior fiscal year.
- Cartesian Therapeutics, Inc. reported Revenue (ASC 606) of $400.0 thousand for fiscal year 2025.
- Cartesian Therapeutics, Inc. showed a decrease of -99.0% in Revenue (ASC 606) compared to the prior fiscal year.
- Cartesian Therapeutics, Inc. reported Net Income of -$130.30 million for fiscal year 2025.
- Cartesian Therapeutics, Inc. showed a decrease of -68.3% in Net Income compared to the prior fiscal year.
- Cartesian Therapeutics, Inc. reported Diluted EPS of $5.02 per share (loss) for fiscal year 2025.
- Cartesian Therapeutics, Inc. showed a decrease of -11.8% in Diluted EPS compared to the prior fiscal year.
- Cartesian Therapeutics, Inc. reported Total Assets of $296.41 million for fiscal year 2025.
- Cartesian Therapeutics, Inc. showed a decrease of -31.9% in Total Assets compared to the prior fiscal year.
- Cartesian Therapeutics, Inc. reported Cash and Equivalents of $125.14 million for fiscal year 2025.
- Cartesian Therapeutics, Inc. showed a decrease of -41.1% in Cash and Equivalents compared to the prior fiscal year.
- Cartesian Therapeutics, Inc. reported Stockholders Equity of -$126.24 million for fiscal year 2025.
- Cartesian Therapeutics, Inc. showed a decrease of -1755.9% in Stockholders Equity compared to the prior fiscal year.
- Cartesian Therapeutics, Inc. reported R&D Expense of $58.03 million for fiscal year 2025.
- Cartesian Therapeutics, Inc. showed an increase of +28.7% in R&D Expense compared to the prior fiscal year.
- Cartesian Therapeutics, Inc. reported Operating Income of -$143.41 million for fiscal year 2025.
- Cartesian Therapeutics, Inc. showed a decrease of -226.7% in Operating Income compared to the prior fiscal year.
- Cartesian Therapeutics, Inc. reported Shares Outstanding of 26.01 million shares for fiscal year 2025.
- Cartesian Therapeutics, Inc. showed an increase of +0.9% in Shares Outstanding compared to the prior fiscal year.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: